一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (545k)  required ID / password
Article in Japanese

Case Report

A case of advanced primary lung squamous cell carcinoma harboring EGFR mutation, treated very effectively by chemotherapy combined with an immune checkpoint inhibitor

Hidekazu Matsushima  Hiroki Ohta  Tomohiro Ohba  Hideaki Yamakawa  Keiichi Akasaka  Masako Amano 

Department of Respiratory Medicine, Saitama Red Cross Hospital

ABSTRACT

A 48-year-old male diagnosed with advanced primary lung squamous cell carcinoma harboring EGFR mutation with a high proportion of PD-L1 was assessed for progressive disease 5 months after administration of osimertinib. We treated him with second-line chemotherapy combined with an immune checkpoint inhibitor; multiple pulmonary metastases rapidly disappeared and the primary tumor decreased in size. We considered this case to be very effectively treated by chemotherapy in combination with an immune checkpoint inhibitor. Even in lung cancer cases harboring driver mutations, including EGFR, chemotherapy in combination with an immune checkpoint inhibitor should be considered, especially in cases with high proportions of PD-L1.

KEYWORDS

Lung cancer  Squamous cell carcinoma  EGFR mutation  Immune checkpoint inhibitor (ICI) 

Received 30 May 2020 / Accepted 1 Sep 2020

AJRS, 10(1): 45-49, 2021

Google Scholar